Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Rating) has received an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. […]